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Abstract Rev-erbK and retinoic acid receptor-related orphan
receptor-K (RORK) are orphan nuclear receptors but their ef-
fects on transcription are opposed. Here, we show that Rev-erbK
was expressed predominantly in vascular smooth muscle cells
(VSMCs) rather than endothelial cells. Overexpression of
Rev-erbK upregulated the expression of interleukin-6 and cyclo-
oxygenase-2, and increased transactivation by NF-UB and
translocation of p65 to the nucleus in A7r5 VSMCs. Further-
more, the expression of Rev-erbK was upregulated by RORK1
but that upregulation was attenuated by Rev-erbK itself in A7r5
VSMCs. These results suggest a regulatory link between Rev-
erbK and the NF-UB pathway.
. 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Nuclear factor-UB (NF-UB) regulates in£ammatory re-
sponses in vascular smooth muscle cells (VSMCs) by upregu-
lating the expression of in£ammatory mediators. NF-UB is a
dimeric transcription factor of belonging to the Rel/NF-UB
family [1,2], and activated NF-UB is present in atherosclerotic
lesions [3]. Several genes upregulated in VSMCs during ath-
erosclerosis and other in£ammatory vascular diseases, includ-
ing interleukin (IL) 6, IL-1, tumor necrosis factor-K (TNF-K),
vascular cell adhesion molecule-1 and intracellular adhesion
molecule-1, contain functional UB elements in their promoter/
enhancer regions [2]. Thus, activation of NF-UB leads to tran-
scription of these proin£ammatory genes.
Rev-erbK is an orphan member of the steroid/thyroid hor-
mone receptor superfamily [4,5]. Rev-erbK binds as a mono-
mer to a retinoic acid receptor-related orphan receptor (ROR)
response elements (RORE) composed of a 6 bp A/T-rich se-
quence immediately preceding a site with the core motif of
RGGTCA (R=A or G) [6]. It has also been shown to bind as
a homodimer to the RevDR2 response element, which is com-
posed of a 6 bp A/T-rich sequence immediately preceding a
site with a tandem repeat of two RGGTCA motifs spaced by
two nucleotides [7]. Because Rev-erbK lacks a conserved car-
boxy-terminal activation domain, it behaves as a transcrip-
tional repressor interacting with other nuclear receptor core-
pressors such as N-CoR [7,8]. Moreover, the Rev-erbK
promoter region contains both a RORE and a RevDR2 ele-
ment. Rev-erbK suppresses activity at its own promoter via
the RevDR2 element [9], which is also essential for the upreg-
ulation of Rev-erbK by peroxisome proliferator-activated re-
ceptor-K (PPARK) [10]. Rev-erbK is expressed in a variety of
tissue types, including brown fat, skeletal muscle, and liver
[4,11]. Although the biological function of Rev-erbK remains
unknown, it has been implicated in adipogenesis [12,13] and
muscle di¡erentiation [14].
RORK is also a member of the nuclear receptor superfam-
ily. The human RORK gene encodes at least four distinct
splicing isoforms, RORK1, K2, K3, and K4 [15]. RORK binds
either as a monomer to a RORE or as a homodimer to a
RevDR2 element and shows constitutive transactivational ac-
tivity via these elements [11,16]. Thus, RORK binds similar
response elements to Rev-erbK but the e¡ects of Rev-erbK and
RORK on transcription are opposed to each other. Interest-
ingly, RORK1 has been shown to suppress TNF-K-induced
expression of proin£ammatory genes in part by inhibiting
the NF-UB signaling pathway in VSMCs [17]. We had previ-
ously shown that RORK1 and RORK4 suppress TNF-K-in-
duced expression of adhesion molecules in part by inhibiting
the NF-UB signaling pathway in human umbilical vein endo-
thelial cells (HUVECs) [18].
Since Rev-erbK and RORK are expressed in the same tis-
sues and regulate similar target genes but in opposite direction
we investigated the e¡ects of Rev-erbK on in£ammation. Here
we report that Rev-erbK is expressed in vascular cells and
regulates their in£ammatory responses.
2. Materials and methods
2.1. Cells and materials
Human aortic VSMCs and HUVECs were maintained in SmBM-2
BulletKit and EBM-2 BulletKit, respectively (all from Clonetics, San
Diego, CA, USA). A7r5 cells (ATCC, Manassas, VA, USA) were
cultured in Dulbecco’s modi¢ed Eagle’s medium containing 10% fetal
bovine serum. HepG2 cells (ATCC) were cultured in minimum essen-
tial medium Eagle containing 10% fetal bovine serum and non-essen-
tial amino acids. TNF-K was purchased from RpD Systems (Abing-
don, UK).
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2.2. Plasmids
Rev-erbK cDNA was cloned from human fetal liver (Human
QUICK-Clone cDNA, Clontech, Palo Alto, CA, USA) and inserted
into the vector pcDNA (Invitrogen, Carlsbad, CA, USA), creating
pcDNA-Rev-erbK. The constructs pTK-RORE-Luc and pcDNA-
RORK1 containing RORK1 cDNA have been described previously
[18]. Plasmid pTK-RevDR2-Luc was constructed by cloning three
tandem copies of RevDR2 (TCCAACTAGGTCACTAGGTCAA-
AG) [19] into the luciferase reporter plasmid, which contained a
thymidine kinase promoter. Plasmids pNF-UB-Luc and pAP-1-Luc
were obtained from Stratagene (La Jolla, CA, USA).
2.3. Reverse transcription polymerase chain reaction (RT-PCR)
analysis
Total RNA was isolated from HUVECs, human aortic VSMCs,
A7r5 cells and HepG2 cells with the RNeasy Mini Kit (Qiagen, Hil-
den, Germany). RT-PCR analysis was performed on 15 ng total RNA
with the GeneAmpEZ rTth RNA PCR Kit (Applied Biosystems,
Foster City, CA, USA). The speci¢c primer sets for the target genes
are as follows: for human Rev-erbK, 5P-ACTTCCCACCATCCCC-
CACT-3P and 5P-GGAAGAAGGGGAGCCGTCAT-3P ; for rat Rev-
erbK, 5P-AACAACCTTTTTGGCGGCTCA-3P and 5P-TGGTGTTG-
CCTTGCCGTAGA-3P ; for human RORK1, 5P-CGGTGCGCAGA-
CAGAGCTATT-3P and 5P-TTGTCTCCACAGATCTTGCATGG-
3P ; for human and rat GAPDH, 5P-AGCTCACTGGCATGGCC-
TTC-3P and 5P-CGCCTGCTTCACCACCTTCT-3P. RT-PCR was
carried out by incubating the reaction mixture for 30 min at 60‡C,
then 60 s at 94‡C, followed by 30 or 35 cycles of 15 s at 94‡C and 15 s
at 58‡C. RT-PCR products were analyzed by electrophoresis in a 3%
agarose gel followed by ethidium bromide staining. Quantitative real-
time RT-PCR was carried out essentially as described [18], using the
above primer sets or the following primers: for rat IL-6, 5P-CCAGC-
CAGTTGCCTTCTTGG-3P and 5P-GCCTCCGACTTGTGAAGTG-
GT-3P ; for rat cyclooxygenase-2 (COX-2), 5P-CCCATGTCAAAA-
CCGTGGTG-3P and 5P-CTGTGTTTGGGGTGGGCTTC-3P. The
mRNA expression levels were normalized by ribosomal RNA
(rRNA) or GAPDH expression (TaqMan control reagent, Applied
Biosystems) and presented as the relative expression level compared
to the expression levels obtained from the control.
2.4. Cell transfection and transcriptional assay
As a measure of transcriptional activity of RORK1 and Rev-erbK,
A7r5 cells were co-transfected using FuGENE6 (Roche, Basel, Swit-
zerland) with 0.5 Wg of pTK-RORE-Luc or pTK-RevDR2-Luc, mixed
with 0.1^0.3 Wg of pcDNA, pcDNA-RORK1 and/or pcDNA-Rev-
erbK. The transfected cells were cultured for 24 h in Dulbecco’s modi-
¢ed Eagle’s medium containing 10% fetal bovine serum and then lu-
ciferase activity was measured (Dual Luciferase Assay Kit; Promega,
Madison, WI, USA). To measure transactivation by NF-UB and acti-
vator protein-1 (AP-1), A7r5 cells were co-transfected using Fu-
GENE6 with 0.5 Wg of either pNF-UB-Luc or pAP-1-Luc, mixed
with 0.1^0.3 Wg of pcDNA, pcDNA-RORK1 or pcDNA-Rev-erbK.
The transfected cells were cultured for 16 h in Dulbecco’s modi¢ed
Eagle’s medium containing 4% charcoal/dextran-treated fetal bovine
serum (Hyclone, Logan, UT, USA). After treatment with 1 or 10 ng/
ml TNF-K for 6 h, luciferase activity was measured. In these experi-
ments, 0.05 Wg pRL-TK (Renilla luciferase reporter, Promega) was
included in the transfection mixture, and the promoter-dependent
transcriptional activity was normalized to Renilla luciferase activity.
For overexpression of Rev-erbK and RORK1, A7r5 cells were trans-
fected using FuGENE6 with 0.2 Wg of pcDNA, pcDNA-Rev-erbK,
and/or pcDNA-RORK1. The transfected cells were cultured for 24 h
in Dulbecco’s modi¢ed Eagle’s medium containing 10% fetal bovine
serum.
2.5. Western blot analysis
Cytoplasmic and nuclear extracts were prepared from A7r5 cells
using CellLyticNu-CLEAR Extraction Kit (Sigma, St. Louis, MO,
USA). The extracts (cytoplasmic protein, 2.5 Wg; nuclear protein, 10
Wg) were analyzed by Western blot analysis using a speci¢c antibody
against NF-UB p65 (sc8008; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), and detected by chemiluminescence.
2.6. Statistical analysis
Quantitative data were expressed as meansTS.D. from three or ¢ve
experiments. Signi¢cance was determined either by Student’s t-test for
comparing two groups or by analysis of variance, followed by Dun-
nett’s test for multiple comparisons. A value of P6 0.05 was consid-
ered signi¢cant.
3. Results
3.1. Rev-erbK is expressed in vascular cells
We ¢rst investigated whether Rev-erbK is expressed in vas-
cular cells by RT-PCR. The expression of Rev-erbK mRNA in
HepG2 cells was con¢rmed (Fig. 1A), as described previously
[9,10]. We found that Rev-erbK was also expressed in HU-
VECs and human aortic VSMCs. Using speci¢c primers for
rat Rev-erbK, the expression of Rev-erbK was detected in rat
A7r5 VSMCs. Quantitative real-time RT-PCR analysis re-
vealed that the relative expression level of Rev-erbK/rRNA
in human VSMCs was clearly higher than that in HUVECs
(Fig. 1B). These data show that Rev-erbK was predominantly
expressed in VSMCs compared to endothelial cells.
3.2. Rev-erbK and RORK1 show opposing transcriptional
activity in A7r5 VSMCs
RORK binds to similar response elements as Rev-erbK
(RORE and RevDR2 element), but the e¡ects of Rev-erbK
and RORK on transcription are opposite [7,8,11,16]. To in-
vestigate their transcriptional activity in VSMCs, we carried
out transient transcriptional assay using a luciferase reporter
plasmid containing RORE (4U) or RevDR2 (3U), along with
an expression vector containing either Rev-erbK or RORK1.
Because of the inability to transfect primary cultured human
VSMCs, rat A7r5 VSMCs were used in these experiments.
When the expression plasmid containing human Rev-erbK
or human RORK1 was transfected into rat A7r5 cells, the
ectopic overexpression of Rev-erbK or RORK1 was con¢rmed
by RT-PCR (Fig. 2A). When the Rev-erbK expression plas-
mid was co-transfected with the luciferase reporter plasmid,
RORE- and RevDR2-dependent luciferase activity decreased
(Fig. 2B,C). In contrast, co-transfection of the RORK1 ex-
pression plasmid with the reporter plasmid led to RORE-
and RevDR2-dependent luciferase activity. These results indi-
cate that RORK1 and Rev-erbK showed opposing transcrip-
Fig. 1. A: Rev-erbK is expressed in vascular cells. Total RNA (15
ng) from HepG2 cells, HUVECs, human aortic VSMCs, and A7r5
VSMCs was analyzed by RT-PCR (35 cycles) as described. B: Rev-
erbK is predominantly expressed in VSMCs. Total RNA from HU-
VECs and human aortic VSMCs was analyzed by quantitative real-
time RT-PCR as described. The normalized expression of human
Rev-erbK by rRNA in VSMCs is presented as the relative expres-
sion to the expression in HUVECs. ***P6 0.001 versus HUVECs.
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tional activity from the RORE and RevDR2 element in A7r5
VSMCs.
3.3. Rev-erbK induces the expression of IL-6 and COX-2 in
A7r5 VSMCs
RORK1 negatively regulates TNF-K-induced proin£amma-
tory gene expression [17,18]. Based on these reports and the
opposing transcriptional activity of RORK1 and Rev-erbK, we
examined the potential involvement of Rev-erbK in regulating
the expression of proin£ammatory genes in VSMCs. We
found that overexpression of Rev-erbK in A7r5 cells led to
increases in the expression of both IL-6 (Fig. 3A) and also
COX-2 (Fig. 3B). In contrast, overexpression of RORK1 did
not a¡ect the basal expression of IL-6 and COX-2 in A7r5
cells.
3.4. Rev-erbK upregulates transactivation by NF-UB in A7r5
VSMCs
Since NF-UB is an important transcriptional factor for reg-
ulating expression of proin£ammatory genes including IL-6
and COX-2, we investigated whether Rev-erbK could upregu-
late transactivation by NF-UB. Co-transfection in A7r5 cells
of the Rev-erbK expression plasmid and the reporter plasmid
that contains NF-UB binding sites (5U) in its promoter, led to
NF-UB-dependent luciferase activity (Fig. 4A). Increasing
amounts of the Rev-erbK expression plasmid gave a dose-de-
pendent upregulation of luciferase activity (Fig. 4B). Interest-
Fig. 2. A: Overexpression of Rev-erbK and RORK1 in A7r5
VSMCs. A7r5 cells were transfected with 0.1 Wg of pcDNA,
pcDNA-Rev-erbK, or pcDNA-RORK1. Total RNA was prepared
and analyzed by RT-PCR (30 cycles) as described. B,C: Rev-erbK
and RORK1 show opposing transcriptional activity in A7r5 VSMCs.
pTK-RORE-Luc plasmid (B) or pTK-RevDR2-Luc plasmid (C) was
transfected along with 0.1 Wg of pcDNA, pcDNA-RORK1, or
pcDNA-Rev-erbK. Luciferase activity was measured after 24 h. The
results are presented as fold induction of the activity of pcDNA-
transfected cells. *P6 0.05, **P6 0.01 versus pcDNA.
Fig. 3. Overexpression of Rev-erbK induces the expression of IL-6
and COX-2 in A7r5 VSMCs. A7r5 cells were transfected with 0.2
Wg of pcDNA, pcDNA-Rev-erbK, or pcDNA-RORK1, and cultured
for 24 h. Total RNA was prepared, and analyzed by quantitative
real-time RT-PCR as described. The normalized expression of rat
IL-6 (A) or rat COX-2 (B) to GAPDH is presented as the relative
expression to the basal expression in pcDNA-transfected cells.
*P6 0.01 versus pcDNA.
Fig. 4. Rev-erbK upregulates NF-UB activation in A7r5 VSMCs. A:
A7r5 cells were co-transfected with the pNF-UB-Luc plasmid, along
with 0.1 Wg of pcDNA, pcDNA-Rev-erbK or pcDNA-RORK1. After
24 h, luciferase activity was measured. The results are presented as
fold induction of the activity of pcDNA-transfected cells. **P6 0.01
versus pcDNA. B: A7r5 cells were co-transfected with the pNF-UB-
Luc plasmid and either pcDNA (0.3 Wg) or pcDNA-Rev-erbK (0.1,
0.2 or 0.3 Wg), and cultured for 16 h. Luciferase activity was mea-
sured after the treatment for 6 h with or without TNF-K as indi-
cated. The results are presented as fold induction of the activity of
pcDNA-transfected and TNF-K-unstimulated cells. *P6 0.05,
**P6 0.01 versus TNF-K unstimulation, #P6 0.05 versus pcDNA
transfection and TNF-K unstimulation. C: A7r5 cells were trans-
fected with 0.3 Wg of either pcDNA or pcDNA-Rev-erbK, and
treated with or without 1 ng/ml TNF-K for 6 h. Cytoplasmic and
nuclear extracts were prepared, and then p65 was detected with the
speci¢c antibody. D: A7r5 cells were co-transfected with the pAP-1-
Luc plasmid, along with 0.3 Wg of pcDNA or pcDNA-Rev-erbK.
After 24 h, luciferase activity was measured.
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ingly, addition of TNF-K led to a potent further induction of
transactivation over either basal levels or the Rev-erbK-in-
duced levels. In contrast, co-transfection in A7r5 cells of the
RORK1 expression plasmid with the reporter plasmid did not
a¡ect the luciferase activity (Fig. 4A). These results indicate
that the net transcriptional response from NF-UB is in£uenced
by the expression levels of Rev-erbK in VSMCs.
3.5. Rev-erbK induces nuclear translocation of p65
Next, to con¢rm the upregulation of NF-UB activity by
overexpression of Rev-erbK, we examined the nuclear trans-
location of p65. NF-UB is composed of p50 and p65 subunits
and translocation of the complex to the nucleus is one of the
critical steps in activating the NF-UB signaling pathway. As
expected, overexpression of Rev-erbK increased the nuclear
abundance of p65 in A7r5 cells, in the same way as TNF-K
treatment (Fig. 4C). Furthermore, overexpression of Rev-erbK
did not a¡ect the p65 mRNA levels in A7r5 cells (data not
shown). Therefore, these data indicate that overexpression of
Rev-erbK upregulates NF-UB signal activation without regu-
lating p65 protein expression.
3.6. Rev-erbK does not regulate transactivation by AP-1 in
A7r5 VSMCs
Since AP-1 is another important transcriptional factor in
regulation of IL-6 and COX-2 expression, we tested whether
Rev-erbK could regulate transactivation by AP-1. There is no
signi¢cant e¡ect on AP-1-dependent transcription when A7r5
cells were co-transfected with the Rev-erbK expression plas-
mid and a reporter plasmid that contains AP-1 binding sites
(7U) in its promoter (Fig. 4D).
3.7. Rev-erbK suppresses RORK1-induced Rev-erbK expression
in A7r5 VSMCs
The promoter region of Rev-erbK contains both a RORE
and a RevDR2 element. The expression of Rev-erbK is upre-
gulated by RORK1 via the RORE in L6 myoblasts [20] and
via the RevDR2 element in HepG2 cells [21]. In contrast, the
transcriptional activity from the promoter region of Rev-erbK
is negatively regulated by Rev-erbK itself [9]. We investigated,
therefore, whether the expression of Rev-erbK could be regu-
lated either by RORK1 or by Rev-erbK itself in VSMCs. Over-
expression of human RORK1 upregulated the expression of
rat Rev-erbK in A7r5 cells (Fig. 5A). The upregulation was
suppressed by co-transfection with the human Rev-erbK ex-
pression plasmid. However, overexpression of human Rev-
erbK alone did not suppress the basal expression levels of
endogenous rat Rev-erbK. Thus, the ectopic overexpression
of human RORK and human Rev-erbK in rat cells leads to
upregulation by RORK1 of the endogenous expression of rat
Rev-erbK but the upregulation is attenuated by Rev-erbK it-
self.
Finally, we tested whether the cross-talk between RORK
and Rev-erbK could be mediated through RORE and/or
RevDR2. Co-transfection of the RORK1 expression plasmid
with the reporter plasmid increased RORE-dependent lucifer-
ase activity in A7r5 VSMCs. Increasing the Rev-erbK expres-
sion plasmid with constant levels of the RORK1 expression
plasmid suppressed the RORK1-induced luciferase activity
(Fig. 5B). Addition of increasing amounts of the Rev-erbK
expression plasmid to the RORK1 expression plasmid led to
a potent suppression of the RevDR2-dependent transcription
(Fig. 5C) in a similar dose-dependent manner to that observed
with RORE-dependent transcription. These results suggest
that Rev-erbK negatively regulates RORK1-induced gene ex-
pression from RORE and RevDR2 in VSMCs.
4. Discussion
Vascular endothelial cells and VSMCs express several nu-
clear receptors including the glucocorticoid receptor and
PPAR which regulate the expression of genes involved in in-
£ammatory responses [22,23]. Recently, RORK was shown to
be expressed in vascular cells [18,24] and to suppress TNF-K-
induced expression of proin£ammatory genes [17,18]. How-
ever, the expression and biological functions of Rev-erbK in
vascular cells remains unclear, although Rev-erbK recognizes
similar response elements to RORK. In this study, we showed
that Rev-erbK was predominantly expressed in VSMCs as
compared to HUVECs. We therefore investigated the e¡ect
of Rev-erbK on the expression of NF-UB-responsive genes in
rat A7r5 VSMCs. Our results showed for the ¢rst time that
overexpression of Rev-erbK upregulates the expression of NF-
UB-responsive genes such as IL-6 and COX-2 in VSMCs.
Fig. 5. A: Rev-erbK suppresses RORK1-induced Rev-erbK expres-
sion in A7r5 VSMCs. A7r5 cells were transfected with pcDNA (0.2
Wg), pcDNA-Rev-erbK (0.1 Wg), or pcDNA-RORK1 (0.1 Wg), or co-
transfected with pcDNA-RORK1 (0.1 Wg) and pcDNA-Rev-erbK
(0.1 Wg). Total RNA was analyzed by quantitative real-time RT-
PCR as described. Rat Rev-erbK expression normalized to GAPDH
is presented as the relative expression to the basal expression of
pcDNA. **P6 0.01 versus pcDNA. B,C: Rev-erbK attenuated tran-
scription by RORK1 in A7r5 VSMCs. A7r5 cells were co-transfected
with either pTK-RORE Luc plasmid (B) or pTK-RevDR2-Luc plas-
mid (C), along with indicated amounts of pcDNA, pcDNA-
RORK1, and/or pcDNA-Rev-erbK. Luciferase activity was measured
after 24 h. The results are presented as fold induction of the activity
of pcDNA-transfected cells. **P6 0.01 versus pcDNA.
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IL-6 is produced by VSMCs, and these cells may be the
primary source of circulating IL-6 during coronary artery dis-
ease. IL-6 contributes to a multitude of physiological and
pathophysiological processes [25]. COX-2 has been shown to
play an important role in in£ammation [26,27]. Its involve-
ment in these pathophysiological processes depends on induc-
tion of its transcription by diverse stimuli. The genes encoding
IL-6 and COX-2 are known to have NF-UB and AP-1 binding
sites in their promoters [2,22,25,28]. In our transient transcrip-
tional assay, Rev-erbK did not upregulate transactivation by
AP-1 but upregulated transactivation by NF-UB (Fig. 4).
Overexpression of Rev-erbK increased translocation of p65
to the nucleus. These results suggest that the upregulation
of IL-6 and COX-2 expression by Rev-erbK is mediated by
upregulating NF-UB activity and, moreover, that Rev-erbK
may upregulate the expression of other NF-UB-responsive
genes. The potency of this upregulation (IL-6 and COX-2,
ca. two-fold; Fig. 3, and NF-UB activation, two-fold; Fig.
4A) is not strong compared to that of pathological stimuli
such as TNF-K. We clearly show, however, that TNF-K-in-
duced NF-UB activation is potentiated by the presence of
Rev-erbK, suggesting that the expression levels of Rev-erbK
in£uence the magnitude of the in£ammatory response by
pathological stimuli such as TNF-K. In contrast, RORK1
overexpression did not a¡ect the basal expression of IL-6
and COX-2 (Fig. 3) or the basal NF-UB activity in A7r5
VSMCs (Fig. 4A). Delerive et al. have reported that
RORK1 overexpression inhibits TNF-K-induced NF-UB acti-
vation in rat PAC1A VSMCs but did not suppress its basal
activity [17]. Taken together, these data suggest that RORK1
does not in£uence the basal activity of NF-UB but regulates
the in£ammatory response by pathological stimuli.
In this report, we describe the potential mechanism by
which the NF-UB signaling pathway is upregulated by Rev-
erbK. Through its suppression of transcriptional activity, Rev-
erbK may negatively regulate an inhibitory molecule(s) of the
NF-UB pathway, whose promoter region has RORE and/or
RevDR2 elements. In contrast, RORK may upregulate the
molecule(s) through its opposing transcriptional activity. In
addition, PPARK may also regulate the similar inhibitory
molecule(s), because PPARK also activates RevDR2-depen-
dent transcription [10] and inhibits proin£ammatory response
[23]. The inhibitor could be a molecule that blocks the activity
of either RIP, TRAF1 or 2, IKK, or blocks IUB degradation
through upregulation of IUB expression, inhibition of IUB
phosphorylation, inhibition of IUB ubiquitination or inhibi-
tion of the proteasome. We also found that Rev-erbK and
RORK1 did not change the expression level of IKKL (data
not shown). It would be of interest to explore further which
molecule is responsible for inhibiting NF-UB activity mediated
by Rev-erbK, and also, RORK or PPARK.
Recently, opposing e¡ects of Rev-erbK and RORK have
been shown in the rat K-fetoprotein far upstream enhancer
[29], rat apoAI promoter [30,31], human apoCIII promoter
[32^34], and human and rat Rev-erbK [9,20,21] by transient
transcriptional assay. These promoters possess a RORE and/
or a RevDR2 element. Interestingly, similarly to the regula-
tion of endogenous expression, RORK1 has been shown to
regulate only the expression of Rev-erbK [20,21]. The tran-
scriptional assay is highly sensitive because the promoter re-
gion of the reporter plasmids used contains repeated consen-
sus elements such as four copies of RORE, or a promoter
with intrinsic high-level expression such as the SV40 promoter
[9] which may lead to overestimation of inhibitory e¡ects.
Therefore, we investigated the regulation of endogenous
Rev-erbK in rat A7r5 VSMCs. Here, in rat A7r5 VSMCs,
we demonstrated that RORK1 upregulated the endogenous
expression of rat Rev-erbK and that up-regulation was then
attenuated by ectopic overexpression of human Rev-erbK.
These results are the ¢rst direct evidence of cross-talk between
Rev-erbK and RORK1 in regulating Rev-erbK expression.
Therefore, we suggest that RORK1 and Rev-erbK may both
contribute to regulating gene expression of Rev-erbK and
genes involved in NF-UB activation in VSMCs (Fig. 6).
In conclusion, our study demonstrates that overexpression
of Rev-erbK upregulates IL-6 and COX-2 expression as well
as NF-UB-dependent transcription. Furthermore, the expres-
sion of Rev-erbK was upregulated by RORK1 and that upreg-
ulation was attenuated by Rev-erbK itself in A7r5 rat VSMCs.
These results provide insights into the role that Rev-erbK
plays in the regulation of the in£ammatory response in
VSMCs.
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